Menu Search
Equities

Ascendis Pharma A/S

ASND:NSQ

Ascendis Pharma A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)129.81
  • Today's Change7.17 / 5.85%
  • Shares traded640.00k
  • 1 Year change+39.58%
  • Beta0.6571
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy8
Outperform6
Hold1
Sell0
Strong Sell0

Share price forecast in EUR

The 15 analysts offering 12 month price targets for Ascendis Pharma A/S (ADR) have a median target of 188.73, with a high estimate of 285.58 and a low estimate of 151.19. The median estimate represents a 45.39% increase from the last price of 129.81.
High120.0%285.58
Med45.4%188.73
Low16.5%151.19

Earnings history & estimates in EUR

On Nov 14, 2024, Ascendis Pharma A/S (ADR) reported 3rd quarter 2024 losses of -1.72 per share. This result was in line with the consensus of the 11 analysts following the company and exceeded last year's 3rd quarter results by 40.28%.
The next earnings announcement is expected on Feb 05, 2025.
Average growth rate+6.02%
Ascendis Pharma A/S (ADR) reported annual 2023 losses of -8.55 per share on Feb 07, 2024.
Average growth rate-22.97%
More ▼

Revenue history & estimates in EUR

Ascendis Pharma A/S (ADR) had 3rd quarter 2024 revenues of 57.83m. This missed the 82.36m consensus estimate of the 11 analysts following the company. This was 72.18% above the prior year's 3rd quarter results.
Average growth rate+38.63%
Ascendis Pharma A/S (ADR) had revenues for the full year 2023 of 266.72m. This was 421.20% above the prior year's results.
Average growth rate+235.75%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.